

(19) World Intellectual Property Organization
International Bureau



G00002



(43) International Publication Date
12 September 2002 (12.09.2002)

PCT

(10) International Publication Number
WO 02/070503 A1

(51) International Patent Classification⁷: **C07D 311/20**

(21) International Application Number: PCT/US01/50438

(22) International Filing Date:
28 December 2001 (28.12.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/271,737 28 February 2001 (28.02.2001) US

(71) Applicants (for all designated States except US): **TARO PHARMACEUTICAL INDUSTRIES LTD.** [US/US]; 5 Skyline Drive, Hawthorne, NY 10532 (US). **BERCOVICI, Sorin** [IL/IL]; 55 Levi Eshkol Street, Apt. 14, POB 772, 55511 Kiriat Ono (IL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **EVRON, Yuval** [IL/IL]; Mitzpe Netofa Settlement, Lower Galilee (IL). **FUXMAN, Osvaldo** [IL/IL]; 20/2, Eliazer Alter Stret, 32984 Haifa (IL). **JAKOEL, Mirela** [IL/IL]; 19A, Katzenelson Street, Kiriat Motzkin (IL). **SASSON, Sbar** [IL/IL]; 42/13, Hanassi Harishon Street, 76302 Rehovot (IL). **ULANENKO, Konstantin** [IL/IL]; 9/15 Tahon Street, 42445 Natania (IL).

(74) Agents: **GOLLIN, Michael, A.** et al.; Venable, Baetjer, Howard & Civiletti, LLP, 1201 New York Avenue, NW, Suite 1000, P.O. Box 34385, Washington, DC 20043-9998 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

Published:

— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



162162

(54) Title: PROCESS FOR PURIFICATION OF WARFARIN ACID, WARFARIN ALKALI METAL SALTS AND CORRESPONDING CLATHRATES

(57) Abstract: An improved procedure for the purification of warfarin acid. Sodium, potassium and lithium warfarin salts and the corresponding clathrates are prepared in high, pharmacopeial grade purity and good yields from the pure warfarin acid and the respective metal salt bases in suitable media. The process for preparing pure warfarin acid from crude warfarin acid starts by suspending the crude acid in a water immiscible solvent, extracting the acid into an aqueous solution of dilute base, separating the resulting aqueous phase and diluting it with a lower alkyl alcohol. The aqueous solution is filtered before being diluted with the lower alkyl alcohol. The solution is acidified to a pH of about 2 to 5 using a suitable acid, such as hydrochloric, sulfuric or phosphoric acid. The resulting suspension is stirred at a temperature of from about 20° C to about 60° C, cooling the suspension below room temperature, filtering the pure warfarin acid and drying.